[HTML][HTML] COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

…, D Gillor, N Postel, MC Mueller, M Müller, K Römer… - Infection, 2020 - Springer
Introduction Data on people living with human immunodeficiency virus (PLWH) in the current
SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-…

[HTML][HTML] Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral …

A Schwenk, A Beisenherz, K Römer, G Kremer… - The American journal of …, 2000 - Elsevier
Background: Highly active antiretroviral treatment (HAART) reduces the risk of wasting in
HIV infection and may alter the prognostic weight of wasting. The phase angle from …

First test of the prompt gamma ray timing method with heterogeneous targets at a clinical proton therapy facility

…, D Prieels, M Priegnitz, KE Römer… - Physics in Medicine …, 2015 - iopscience.iop.org
Ion beam therapy promises enhanced tumour coverage compared to conventional
radiotherapy, but particle range uncertainties significantly blunt the achievable precision. …

[HTML][HTML] Compton Camera and Prompt Gamma Ray Timing: Two Methods for In Vivo Range Assessment in Proton Therapy

…, T Kormoll, G Pausch, J Petzoldt, KE Römer… - Frontiers in …, 2016 - frontiersin.org
Proton beams are promising means for treating tumors. Such charged particles stop at a
defined depth, where the ionization density is maximum. As the dose deposit beyond this distal …

Detection systems for range monitoring in proton therapy: Needs and challenges

G Pausch, J Berthold, W Enghardt, K Römer… - Nuclear Instruments and …, 2020 - Elsevier
In-vivo range verification has been a hot topic in particle therapy for about two decades. In
spite of vast efforts made by research groups all over the world, clinical devices and …

[HTML][HTML] Dynamics and durability of HIV-1 neutralization are determined by viral replication

…, E Heger, E Knops, C Wyen, T Kümmerle, K Römer… - Nature Medicine, 2023 - nature.com
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent
infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet …

Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?

A Jütte, A Schwenk, C Franzen, K Römer, F Diet… - Aids, 1999 - journals.lww.com
We have recently observed five cases of myocardial infarction (MI) within 6 months in one
HIV outpatient department. All patients had been on protease inhibitor (PI) treatment for a …

Summary of German‐Austrian HIV PrEP guideline

…, HJ Stellbrink, S Esser, A Haberl, K Römer… - HIV …, 2019 - Wiley Online Library
Objectives HIV Pre‐Exposure prophylaxis (PrEP) is a strategy to reduce HIV transmission in
people at risk. Aim of this first German‐Austrian PrEP guideline is to provide professional …

HIV-Erstdiagnosen in Deutschland im Jahr 2014–eine regionale Analyse

…, A Meurer, R Pauli, N Postel, K Römer… - Das …, 2022 - thieme-connect.com
Hintergrund Über die qualitative Bedeutung der testenden Zentren im Gesundheitswesen ist
wenig bekannt, gleichzeitig stellen die Late-Presenter eine immer noch große Gruppe bei …

Linearization of gamma energy spectra in scintillator-based commercial instruments

Y Kong, G Pausch, K Romer, A Kreuels… - … on Nuclear Science, 2010 - ieeexplore.ieee.org
This paper presents a novel technique developed for linearizing the energy spectra of
radiation detectors in commercial radioisotope identification devices. Based on few spectrum …